<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="189469">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626873</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000584233</org_study_id>
    <secondary_id>VU-VICC-GYN-0720</secondary_id>
    <secondary_id>VU-VICC-061292</secondary_id>
    <nct_id>NCT00626873</nct_id>
  </id_info>
  <brief_title>Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary</brief_title>
  <official_title>Microvascular Perfusion Sonographic Imaging to Detect Early Stage Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: New diagnostic procedures, such as contrast-enhanced ultrasonography, may be an
      effective method of finding ovarian cancer.

      PURPOSE: This clinical trial is studying how well contrast-enhanced ultrasonography works in
      diagnosing early-stage ovarian cancer in patients with an adnexal mass undergoing surgery to
      remove the ovary.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine whether use of a contrast agent improves the images of the ovaries during
           ultrasonography.

      OUTLINE: This is a multicenter study.

      Patients may undergo baseline transabdominal or transvaginal ultrasonography, if not already
      done. Patients then undergo contrast-enhanced transabdominal or transvaginal ultrasonography
      using perflutren lipid microspheres (Definity®) IV.

      Pathology reports from tissue collected during subsequent oophorectomy is analyzed and
      compared with ultrasonography findings.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ovarian microvascularity</measure>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>perflutren lipid microspheres</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical chart review</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of adnexal mass

          -  Scheduled to undergo surgical oophorectomy

        PATIENT CHARACTERISTICS:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  No known respiratory failure as manifested by signs and symptoms of carbon dioxide
             retention or hypoxemia

          -  No pulmonary vasculitis

          -  No known history of severe emphysema

          -  No known history of pulmonary emboli

          -  No other condition that causes pulmonary hypertension due to compromised pulmonary
             arterial vasculature

          -  No known history of severe pulmonary hypertension (i.e., systolic pulmonary artery
             pressures &gt; 90 mm Hg)

          -  No known history of congenital heart defect that creates a bidirectional or
             right-to-left shunt

          -  No worsening or clinically unstable congestive heart failure

          -  No known acute myocardial infarction or acute coronary syndromes

          -  No known serious ventricular arrhythmias

          -  Not at high risk for arrhythmia due to prolongation of the QT interval

          -  No known or suspected hypersensitivity to blood, blood products, or albumin

          -  No known hypersensitivity to perflutren

          -  No known or suspected hypersensitivity to octafluoropropane or any other ingredients
             of perflutren lipid microspheres (Definity®)

          -  No mental status problems, illiteracy, or other circumstance that would preclude
             giving informed consent

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur C. Fleischer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center - Cool Springs</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur Fleischer</last_name>
      <phone>615-322-2826</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center at Franklin</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur Fleischer</last_name>
      <phone>615-322-2826</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Vanderbilt-Ingram Cancer Center</last_name>
      <phone>800-811-8480</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <lastchanged_date>August 11, 2009</lastchanged_date>
  <firstreceived_date>February 28, 2008</firstreceived_date>
  <keyword>ovarian germ cell tumor</keyword>
  <keyword>ovarian epithelial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
